Hinge Health (HNGE) is scheduled to present at the 5th TestMu Conference on August 19, 2026, where Head of AI Rashi Agrawal will speak about the company’s use of AI in musculoskeletal care.

At a share price of $89.98, Hinge Health has seen strong recent momentum, with a 30 day share price return of 21.09%, a 90 day share price return of 69.84% and a year to date share price return of 97.50%. Its 1 year total shareholder return is 63.39%, suggesting investors have been steadily reassessing the company ahead of its AI focused conference appearance.

If you are interested in how AI is reshaping healthcare beyond Hinge Health, this is a good moment to scan the market using the 40 healthcare AI stocks

Bulls point to Hinge Health’s AI story, recent returns, and revenue and net income figures. Bears worry the share price has simply run too far. Which case lines up better with today’s valuation metrics?

Most Popular Narrative: 100% Undervalued

Hinge Health’s most followed narrative assigns a fair value of $90.87, which is close to the last close of $89.98. However, the modelled long term cash flow value sits far higher at $369.58, creating a wide gap that many investors will want to understand before the TestMu appearance.

Analysts are assuming Hinge Health's revenue will grow by 27.9% annually over the next 3 years.

Analysts assume that profit margins will increase from -79.1% today to 23.0% in 3 years time.

Curious what kind of earnings profile those revenue and margin shifts would support? The most followed narrative leans on a future profit base and a premium earnings multiple that together underpin this fair value call.

This narrative applies a 7.11% discount rate to those future cash flows. This is the hurdle used to bring all the projected revenue, earnings and margins back into today’s dollars. It also assumes a stronger return on equity profile and improving profitability that would need to line up with how Hinge Health executes on its AI driven MSK platform and broader product expansion.

Result: Fair Value of $90.87 (UNDERVALUED)

Still, the Hinge Health narrative depends on employers and health plans maintaining appetite for digital MSK solutions, and on AI tools scaling without regulatory or data privacy setbacks.

Another View: Hinge Health Through a P/E Lens

While the SWS DCF work suggests Hinge Health is trading well below its future cash flow value, the picture looks less comfortable when you zoom in on the P/E ratio. HNGE trades on 67.7x earnings, slightly above peers at 67.2x and far above the US Healthcare industry at 25.5x.

The fair ratio for Hinge Health is 37.8x, which is well below today’s multiple. That gap points to valuation risk if the market later moves closer to the fair ratio, especially after a strong share price run. The question for you is whether current growth expectations fully justify paying this kind of premium.

To see how the current multiple compares with a more detailed breakdown, review the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and caution around Hinge Health, this is a good time to move quickly and test the numbers yourself. To see why some investors are focused on the upside, review the 3 key rewards

Looking for more investment ideas beyond Hinge Health?

If Hinge Health has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas sourced directly from Simply Wall Street’s data driven screeners.

• Target strong upside potential by checking companies that screen as high quality and potentially mispriced through the 49 high quality undervalued stocks.
• Protect your capital with companies that pair resilience and lower risk scores by reviewing the 74 resilient stocks with low risk scores.
• Seek out underfollowed opportunities that still show solid fundamentals using the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.